Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.

Ketter N, H Brashear R, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, H Arrighi M

J Alzheimers Dis. 2017; 57(2):557-573. PMID: 28269765. Abstract